Krystal Biotech (KRYS) CAO sells shares and receives fresh stock awards

Rhea-AI Filing Summary

Krystal Biotech, Inc. Chief Accounting Officer Kathryn Romano reported a mix of stock sales, vesting, and new equity awards. On March 2, 2026, she completed an open-market sale of 750 shares of common stock at $267.60 per share under a pre-arranged Rule 10b5-1 trading plan, leaving 22,366 common shares held directly.

On February 27, 2026, 7,500 performance stock units vested after meeting 2024 performance goals, and 550 restricted stock units vested from a 2025 grant, both converting into common shares. To cover tax withholding on these vestings, 3,262 and 240 common shares, respectively, were surrendered to the company at a reference price of $275.64 per share.

Also on February 27, Romano received new equity incentives: a stock option for 13,575 shares and a new grant of 5,442 restricted stock units, each vesting in four equal annual installments beginning February 27, 2027.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROMANO KATHRYN

(Last) (First) (Middle)

C/O KRYSTAL BIOTECH, INC.

2100 WHARTON STREET, SUITE 701

(Street)

PITTSBURGH PA 15203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		M		7,500(1)	A	$0	26,068	D
Common Stock	02/27/2026		F		3,262(2)	D	$275.64(3)	22,806	D
Common Stock	02/27/2026		M		550(4)	A	$0	23,356	D
Common Stock	02/27/2026		F		240(5)	D	$275.64(3)	23,116	D
Common Stock	03/02/2026		S		750(6)	D	$267.6	22,366	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(1)	02/27/2026		M			7,500	(1)	(1)	Common Stock	7,500	$0	0	D
Restricted Stock Units	(4)	02/27/2026		M			550	(4)	(4)	Common Stock	550	$0	1,650	D
Stock Option (Right to Buy)	$275.64	02/27/2026		A		13,575		(7)	02/26/2036	Common Stock	13,575	$0	13,575	D
Restricted Stock Units	(8)	02/27/2026		A		5,442(9)		(10)	(10)	Common Stock	5,442	$0	5,442	D

Explanation of Responses:

1. 15,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026.

2. Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 7,500 RSUs on February 27, 2026.

3. The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.

4. 2,200 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026.

5. Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 550 RSUs on February 27, 2026.

6. The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2025. The Rule 10b5-1 trading plan terminated upon completion of the sale of the shares of the Company's common stock reported on this Form 4, which represented the completion of all sales of the Company's common stock subject to the Rule 10b5-1 trading plan.

7. The stock options vest in four equal annual installments beginning on February 27, 2027.

8. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date.

9. The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates.

10. The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027.

Remarks:

	/s/ Kathryn Romano	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Kathryn Romano report at Krystal Biotech (KRYS)?

Kathryn Romano reported an open-market sale of 750 Krystal Biotech shares, vesting of performance and restricted stock units into common shares, tax-withholding share surrenders, and new grants of stock options and restricted stock units as part of her equity compensation package.

How many Krystal Biotech (KRYS) shares did Kathryn Romano sell and at what price?

She sold 750 shares of Krystal Biotech common stock at $267.60 per share. The transaction was an open-market sale executed under a Rule 10b5-1 trading plan and represented the completion of all sales covered by that pre-arranged plan.

What equity awards vested for Kathryn Romano at Krystal Biotech (KRYS)?

7,500 performance stock units and 550 restricted stock units vested for Kathryn Romano. Each unit converted into one share of Krystal Biotech common stock after meeting performance criteria and service conditions tied to specific vesting dates approved by the company.

Why were shares surrendered for taxes in the Krystal Biotech (KRYS) Form 4?

Romano surrendered 3,262 and 240 Krystal Biotech shares to cover tax withholding on the vesting of 7,500 performance stock units and 550 restricted stock units. These tax-withholding dispositions used a reference closing price of $275.64 per share on February 27, 2026.

What new stock option and RSU grants did Kathryn Romano receive from Krystal Biotech (KRYS)?

She received a stock option for 13,575 shares and a grant of 5,442 restricted stock units. Both awards vest in four equal annual installments starting February 27, 2027, contingent on her continued service to Krystal Biotech on each vesting date.

How many Krystal Biotech (KRYS) shares does Kathryn Romano hold after these transactions?

After the reported transactions, Romano directly holds 22,366 shares of Krystal Biotech common stock. She also holds derivative interests, including vested and unvested stock options and restricted stock units that may convert into additional shares over future vesting periods.